PACB

Pacific Biosciences of California, Inc.

1.32

USD

PACB Earnings Reports

Positive Surprise Ratio

PACB beat 20 of 40 last estimates.

50%

Next Report

Date of Next Report

Apr 07, 2026

Estimate for Q1 27 (Revenue/ EPS)

$51.65M

-$0.13

Implied change from Q4 25 (Revenue/ EPS)

+15.69%

+8.33%

Implied change from Q1 26 (Revenue/ EPS)

Pacific Biosciences of California, Inc. earnings per share and revenue

On Feb 12, 2026, PACB reported earnings of -0.12 USD per share (EPS) for Q4 25, beating the estimate of -0.15 USD, resulting in a 20.27% surprise. Revenue reached 44.65 million, compared to an expected 43.38 million, with a 2.91% difference. The market reacted with a +5.97% price change (close before vs. close after earnings).

Looking ahead to Q1 27, 5 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 51.65 million USD, implying an increase of 8.33% EPS, and increase of 15.69% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Alpha Tau Medical Ltd. Ordinary Shares

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.12

Actual

-$0.08

Surprise

+36.51%

ClearPoint Neuro, Inc. Common Stock

Report Date

Mar 17, 2026 For Q4 25

Estimate

-$0.20

Actual

-$0.27

Surprise

-32.35%

Stereotaxis, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.06

Surprise

+10.04%

Hyperfine, Inc. Class A Common Stock

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.08

Surprise

+1.96%

Rapid Micro Biosystems, Inc. Class A Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.22

Actual

-$0.28

Surprise

-23.35%

Neuronetics, Inc. Common Stock

Report Date

Mar 17, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.10

Surprise

+8.09%

InspireMD, Inc.

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.14

Surprise

+29.01%

Tenon Medical, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.36

Actual

-$0.22

Surprise

+40.09%

Nuwellis, Inc. Common Stock

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$1.59

Actual

-$1.50

Surprise

+5.73%

FAQ

What were Pacific Biosciences of California, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Pacific Biosciences of California, Inc. reported EPS of -$0.12, beating estimates by 20.27%, and revenue of $44.65M, 2.91% above expectations.

How did the market react to Pacific Biosciences of California, Inc.'s Q4 2025 earnings?

The stock price moved up 5.97%, changed from $2.01 before the earnings release to $2.13 the day after.

When is Pacific Biosciences of California, Inc. expected to report next?

The next earning report is scheduled for Apr 07, 2026.

What are the forecasts for Pacific Biosciences of California, Inc.'s next earnings report?

Based on 5 analysts, Pacific Biosciences of California, Inc. is expected to report EPS of -$0.13 and revenue of $51.65M for Q1 2027.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.